Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib +/- Paclitaxel in Chinese Patients with Advanced Solid Tumors
NCT04742036Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capivasertib in solid tumor (advanced stage), sponsored by AstraZeneca. Primary endpoints: Area under the plasma concentration-time curve from time zero to 12 hours post-dose, Maximum plasma concentration at 6 months and 2 more. Started Feb 2021; status: completed.
02
Drugs
capivasertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04742036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742036.